[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT06809725":3,"trial-entities:NCT06809725":80,"trial-summary:NCT06809725":85},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":22,"study_type":26,"primary_purpose":27,"phases":28,"enrollment_info":30,"interventions":33,"primary_outcomes":40,"secondary_outcomes":51,"sex":52,"minimum_age":53,"maximum_age":54,"healthy_volunteers":55,"eligibility_criteria":56,"std_ages":60,"locations":62,"central_contacts":72,"overall_officials":73,"references":78,"see_also_links":79},"NCT06809725","1002","Software Validation Study-Cognitive Status Indicator","Validation of the SPARK Scan Cognitive Status Indicator Software Concordance With Clinical Diagnosis in Humans With Unimpaired, Mild Cognitive Impairment and Dementia Status, With and Without Alzheimer's Disease","ENROLLING_BY_INVITATION","2026-06-01","2025-07","2025-07-18","2025-03-31","Spark Neuro Inc.","INDUSTRY",false,"The SPARK Cognitive Status Indicator software uses an algorithm to assess a resting state EEG recording as being consistent with a cognitive status of unimpaired, mild cognitive impairment (MCI; MCI AD- or MCI AD+), or dementia (dementia AD-, or dementia AD+). This study will compare SPARK Cognitive Status Indicator output to Adjudication Committee panel-based diagnosis of cognitive status and Alzheimer's disease.","Up to 600 subjects (and informants) may be enrolled and have a brain scan, cognitive, and blood assessments collected:\n\nVisit 1-Screening:\n\n-Salzburg (SDTP)- remote via telephone or video visit\n\nVisit 2\u002F3-Evaluations:\n\n* EEG Scan (brain scan)\n* Mini-Mental State Exam (MMSE)-at home visit\n* Functional Assessment Staging Tool (FAST)- at home via video visit\n* blood- Amyloid Beta 42\u002F40 ratio, p tau- at laboratory or home visit There are three instances of subject engagement with the study team after informed consent. One, during screening which may be a remote visit and and two different home or remote visits (or laboratory visit). The study participation ends when all of the assessments have been collected. The total duration of subject participation should be no more than 2-3 days within a 90 day period.\n\nThe output of the investigational software used in the analysis to determine a identification of cognitive and Alzheimer's status based the data from the EEG scan shall be compared to the identification of cognitive and Alzheimer's status from a group of dementia specialists forming an Adjudication Committee which shall review all data (except for investigational device output).",[19,20,21],"Alzheimer Disease","Mild Cognitive Impairment","Dementia",[23,24,20,25],"Alzheimer","dementia","EEG","INTERVENTIONAL","DIAGNOSTIC",[29],"NA",{"count":31,"type":32},600,"ESTIMATED",[34],{"type":35,"name":36,"description":37,"armGroupLabels":38},"DIAGNOSTIC_TEST","SPARK Cognitive Status Indicator (software support data collected via EEG)","The SPARK Cognitive Status Indicator software (collected via EEG) is being validated to aid in the diagnosis of Alzheimer's disease in persons aged 65-90 with suspected cognitive impairment. The device, once validated, shall provide a clinician with a \"positive\" or \"negative\" output to indicate whether the subject's electroencephalogram (EEG) is consistent with EEGs of subjects diagnosed with Alzheimer's disease.",[39],"Dementia subjects",[41,45,48],{"measure":42,"description":43,"timeFrame":44},"Accuracy of SPARK Cognitive Status Indicator compared to Adjudicated cognitive status","Software output of investigational device shall be compared to the cognitive status as determined by an Adjudication Committee","Day 1",{"measure":46,"description":47,"timeFrame":44},"Sensitivity of SPARK Cognitive Status Indicator when identifying Alzheimer's disease in impaired subjects","Software output sensitivity will be computed from device AD+ output compared to the Adjudication Committee findings of AD positive cases (MCI and dementia subjects)",{"measure":49,"description":50,"timeFrame":44},"Specificity of SPARK Cognitive Status Indicator when identifying Alzheimer's disease in impaired subjects","Software output specificity will be computed from device AD- output compared to the Adjudication Committee findings of AD negative cases (MCI and dementia subjects)",[],"ALL","65 Years","90 Years",true,{"inclusion":57,"exclusion":58,"raw_text":59},[],[],"Inclusion Criteria:\n\nUnimpaired subjects:\n\nTo be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Provision of signed and dated informed consent form\n2. Stated willingness to comply with all study procedures and availability for the duration of the study\n3. Male or female, aged 65 to 90 at the time of consent\n4. Have a Salzburg Dementia Test Prediction (SDTP) score \\>= 24.\n5. Informant, available and willing (remotely or in-person) to provide information about subject cognitive functioning\n6. No Medical History of cognitive impairment\n\nMild Cognitive Impairment subjects:\n\nTo be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. 1\\. Provision of signed and dated informed consent form\n2. Stated willingness to comply with all study procedures and availability for the duration of the study\n3. Male or female, aged 65 to 90 at the time of consent\n4. Have a Salzburg Dementia Test Prediction (SDTP) score \\\u003C 24.\n5. Informant, available and willing (remotely or in-person) to provide information about subject cognitive functioning\n6. Suspected or diagnosed with a mild cognitive issue\n\nDementia subjects:\n\nTo be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Provision of signed and dated informed consent form-legally authorized representative or individual\n2. Stated willingness to comply with all study procedures and availability for the duration of the study\n3. Male or female, aged 65 to 90 at the time of consent\n4. Have a Salzburg Dementia Test Prediction (SDTP) score \\\u003C 24.\n5. Informant, available and willing (remotely or in-person) to provide information about subject cognitive functioning\n6. Exhibiting and diagnosed with moderate or severe cognitive issue\n\nInformants:\n\nTo be eligible to participate as an informant in this study, an individual must meet all of the following criteria:\n\n1\\. Provision of signed and dated informed consent form 2. Typically spends 2 or more hours per month with subject. 3. Available and willing (remotely or in-person) to provide information about subject cognitive functioning\n\n\\-\n\nExclusion Criteria:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1\\. Currently experiencing a skin disease on scalp that would affect electrode contacts in the opinion of the user\n\n\\-",[61],"OLDER_ADULT",[63],{"facility":64,"city":65,"state":66,"zip":67,"country":68,"geoPoint":69},"Remote","Miami","Florida","33101","United States",{"lat":70,"lon":71},25.77427,-80.19366,[],[74],{"name":75,"affiliation":76,"role":77},"Keith Yoder, PI, PhD","SPARK Neuro","PRINCIPAL_INVESTIGATOR",[],[],{"nct_id":4,"conditions":81,"biomarkers":84},[82,21,83],"Alzheimer's Disease","Mild cognitive disorder",[],{"nct_id":4,"found":15,"summary":86,"prompt_version":86},null]